# A Study Evaluating the Effectiveness and Safety of Pulsed Field Ablation Using the FARAPULSE™ System for Electrical Isolation of Pulmonary Veins and Superior Vena Cava

Study · id `cardio:ct-nct07162597` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07162597](<https://clinicaltrials.gov/study/NCT07162597>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07162597

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07162597. Allocation not applicable; no masking; primary purpose treatment. Start 2025-10-01 (anticipated); primary completion 2028-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07162597, source copy `cardio:ctgov-nct07162597-2025-09-09`, retrieved 2026-10-26)
- Planned start: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT07162597, source copy `cardio:ctgov-nct07162597-2025-09-09`, retrieved 2026-10-26)
- Primary completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07162597, source copy `cardio:ctgov-nct07162597-2025-09-09`, retrieved 2026-10-26)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07162597, source copy `cardio:ctgov-nct07162597-2025-09-09`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07162597-2025-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Evaluating the Effectiveness and Safety of Pulsed Field Ablation Using the FARAPULSE™ System for Electrical Isolation of Pulmonary Veins and Superior Vena Cava
- Condition: Atrial Fibrillation (Paroxysmal)
- Intervention (Device): Pulsed Field Ablation
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER
- Collaborator: Boston Scientific Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)
- Registry lists this organization as a collaborator: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 9bfcb9095098fe6a6e0c507bb183a87bf3823f103bb0d0c106d00d1f7a6a59e1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
